Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177134 | 1.00 | POLB (0.35) | POLBTP53BP1RAB9AITGB3ITGA2B | |
| SCHEMBL20074003 | 0.89 | — | — | |
| SCHEMBL19320413 | 0.89 | POLB (0.31) | POLBITGB3ITGA2B | |
| SCHEMBL19543090 | 0.88 | SIRT5 (0.33) | POLB | |
| SCHEMBL19483326 | 0.86 | KISS1R (0.39) | — | |
| SCHEMBL19483312 | 0.86 | KISS1R (0.39) | — | |
| SCHEMBL26654410 | 0.85 | TP53BP1 (0.33) | POLBTP53BP1 | |
| SCHEMBL20682455 | 0.85 | SIRT6 (0.40) | POLBITGB3ITGA2B | |
| SCHEMBL20650879 | 0.85 | TP53BP1 (0.33) | POLBTP53BP1 | |
| SCHEMBL15999827 | 0.84 | SIRT6 (0.39) | TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230348671-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, AND PREPARATION METHOD THEREFOR, AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348671-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, AND PREPARATION METHOD THEREFOR, AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEATTLE GENETICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | PAICS, FCGRT, DNPEP | POLB 3535/4885TP53BP1 3982/4885RAB9A 4057/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | POLB 2833/4885TP53BP1 4097/4885RAB9A 897/4885 |
| US-20230348671-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, AND PREPARATION METHOD THEREFOR, AND USE THEREOF | THEM6, WEE1, SLC10A1 | POLB 4179/4885TP53BP1 4156/4885RAB9A 3050/4885 |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | POLB 2236/4885TP53BP1 4073/4885RAB9A 736/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | POLB 3984/4885TP53BP1 4514/4885RAB9A 1266/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | POLB 2406/4885TP53BP1 4696/4885RAB9A 1180/4885 |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | POLB 2824/4885TP53BP1 3974/4885RAB9A 935/4885 |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | SLC10A1, SLC10A2, NOTUM | POLB 3615/4885TP53BP1 4093/4885RAB9A 3797/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | POLB 4133/4885TP53BP1 4786/4885RAB9A 2445/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | POLB 4133/4885TP53BP1 4786/4885RAB9A 2445/4885 |
| US-20160310612-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | POLB 1796/4885TP53BP1 3417/4885RAB9A 3832/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | POLB 4133/4885TP53BP1 4786/4885RAB9A 2445/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | POLB 2824/4885TP53BP1 3974/4885RAB9A 935/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | POLB 1298/4885TP53BP1 1659/4885RAB9A 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.